Cargando…
Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibody–Consuming Effect?
Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the CNS with severe involvement of the optic nerve and spinal cord. Highly specific serum IgG autoantibodies (NMO-IgG) that react with aquaporin-4 (AQP4), the most abundant CNS water channel protein, are found in patients with NM...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association of Neuropathologists
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327561/ https://www.ncbi.nlm.nih.gov/pubmed/25668569 http://dx.doi.org/10.1097/NEN.0000000000000173 |
_version_ | 1782357108971274240 |
---|---|
author | Aboulenein-Djamshidian, Fahmy Höftberger, Romana Waters, Patrick Krampla, Wolfgang Lassmann, Hans Budka, Herbert Vincent, Angela Kristoferitsch, Wolfgang |
author_facet | Aboulenein-Djamshidian, Fahmy Höftberger, Romana Waters, Patrick Krampla, Wolfgang Lassmann, Hans Budka, Herbert Vincent, Angela Kristoferitsch, Wolfgang |
author_sort | Aboulenein-Djamshidian, Fahmy |
collection | PubMed |
description | Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the CNS with severe involvement of the optic nerve and spinal cord. Highly specific serum IgG autoantibodies (NMO-IgG) that react with aquaporin-4 (AQP4), the most abundant CNS water channel protein, are found in patients with NMO. However, in vivo evidence combining the results of AQP4 antibody serum levels and brain pathology is lacking. We report a patient with NMO whose AQP4 antibody levels decreased simultaneously with clinical deterioration caused by the development of a tumor-like brain lesion. In the seminecrotic biopsied brain lesion, there was activated complement complex, whereas only very scattered immunoreactivity to AQP4 protein was detectable. The decrease in serum AQP4 antibody levels and the loss of AQP4 in the tumor-like lesion could represent a “serum antibody–consuming effect” during lesion formation. |
format | Online Article Text |
id | pubmed-4327561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | American Association of Neuropathologists |
record_format | MEDLINE/PubMed |
spelling | pubmed-43275612015-03-05 Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibody–Consuming Effect? Aboulenein-Djamshidian, Fahmy Höftberger, Romana Waters, Patrick Krampla, Wolfgang Lassmann, Hans Budka, Herbert Vincent, Angela Kristoferitsch, Wolfgang J Neuropathol Exp Neurol Brief Report Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the CNS with severe involvement of the optic nerve and spinal cord. Highly specific serum IgG autoantibodies (NMO-IgG) that react with aquaporin-4 (AQP4), the most abundant CNS water channel protein, are found in patients with NMO. However, in vivo evidence combining the results of AQP4 antibody serum levels and brain pathology is lacking. We report a patient with NMO whose AQP4 antibody levels decreased simultaneously with clinical deterioration caused by the development of a tumor-like brain lesion. In the seminecrotic biopsied brain lesion, there was activated complement complex, whereas only very scattered immunoreactivity to AQP4 protein was detectable. The decrease in serum AQP4 antibody levels and the loss of AQP4 in the tumor-like lesion could represent a “serum antibody–consuming effect” during lesion formation. American Association of Neuropathologists 2015-03 2015-02-13 /pmc/articles/PMC4327561/ /pubmed/25668569 http://dx.doi.org/10.1097/NEN.0000000000000173 Text en Copyright © 2015 by the American Association of Neuropathologists, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. |
spellingShingle | Brief Report Aboulenein-Djamshidian, Fahmy Höftberger, Romana Waters, Patrick Krampla, Wolfgang Lassmann, Hans Budka, Herbert Vincent, Angela Kristoferitsch, Wolfgang Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibody–Consuming Effect? |
title | Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibody–Consuming Effect? |
title_full | Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibody–Consuming Effect? |
title_fullStr | Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibody–Consuming Effect? |
title_full_unstemmed | Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibody–Consuming Effect? |
title_short | Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibody–Consuming Effect? |
title_sort | reduction in serum aquaporin-4 antibody titers during development of a tumor-like brain lesion in a patient with neuromyelitis optica: a serum antibody–consuming effect? |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327561/ https://www.ncbi.nlm.nih.gov/pubmed/25668569 http://dx.doi.org/10.1097/NEN.0000000000000173 |
work_keys_str_mv | AT abouleneindjamshidianfahmy reductioninserumaquaporin4antibodytitersduringdevelopmentofatumorlikebrainlesioninapatientwithneuromyelitisopticaaserumantibodyconsumingeffect AT hoftbergerromana reductioninserumaquaporin4antibodytitersduringdevelopmentofatumorlikebrainlesioninapatientwithneuromyelitisopticaaserumantibodyconsumingeffect AT waterspatrick reductioninserumaquaporin4antibodytitersduringdevelopmentofatumorlikebrainlesioninapatientwithneuromyelitisopticaaserumantibodyconsumingeffect AT kramplawolfgang reductioninserumaquaporin4antibodytitersduringdevelopmentofatumorlikebrainlesioninapatientwithneuromyelitisopticaaserumantibodyconsumingeffect AT lassmannhans reductioninserumaquaporin4antibodytitersduringdevelopmentofatumorlikebrainlesioninapatientwithneuromyelitisopticaaserumantibodyconsumingeffect AT budkaherbert reductioninserumaquaporin4antibodytitersduringdevelopmentofatumorlikebrainlesioninapatientwithneuromyelitisopticaaserumantibodyconsumingeffect AT vincentangela reductioninserumaquaporin4antibodytitersduringdevelopmentofatumorlikebrainlesioninapatientwithneuromyelitisopticaaserumantibodyconsumingeffect AT kristoferitschwolfgang reductioninserumaquaporin4antibodytitersduringdevelopmentofatumorlikebrainlesioninapatientwithneuromyelitisopticaaserumantibodyconsumingeffect |